On Tuesday, Shares of Amazon.com, Inc. (NASDAQ:AMZN), gained 0.64% to $659.68.
Amazon recently declared that Amazon Echo, the best-selling device designed around your voice, will be available in more than 3,000 stores around the country in time for the holiday shopping season. Customers will be able to visit select locations of The Home Depot, Staples, Sears, Brookstone, RadioShack, Fred Meyer, P.C. Richard & Son, in addition to several other retailers to experience and purchase Echo.
“Amazon Echo is a must-have gift this holiday season, and we’re excited to work with retailers across the country to make Echo available to their customers,” said Greg Hart, Vice President, Amazon Echo and Alexa Voice Services. “Using only your voice to play music, control your lights, and ask questions is magical, so it’s great that people will be able to visit local stores and try it for themselves.”
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates through the North America, International, and Amazon Web Services (AWS) segments. The company serves consumers through retail websites, such as amazon.com, amazon.ca, and amazon.com.mx, which primarily comprise merchandise and content purchased for resale from vendors and those offered by third-party sellers.
Shares of Medtronic PLC (NYSE:MDT), inclined 0.71% to $76.40, during its last trading session.
Medtronic plc, declared that the Medtronic Micra Transcatheter Pacing System (TPS) was successfully implanted in nearly all patients in the trial - 99.2 percent - and met its safety and effectiveness endpoints with wide margins. These data, from the Medtronic Micra® TPS Global Clinical Trial, were presented during a late-breaking Special Report session recently at the 2015 American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine.
“We are extremely happy with the remarkably successful implant rates and safety profile of the Micra pacemaker, counting the absence of device dislodgments. We are especially confident in these results because the trial comprised patients with serious comorbidities from 19 countries on five continents around the world,” said Dwight Reynolds, M.D., trial principal investigator and regent`s professor and chief of the Cardiovascular Section at the University of Oklahoma Health Sciences Center. “The Micra TPS not only met its trial endpoints, but also offered a noteworthyreduction in healthcare utilization due to fewer major complications contrast to conventional pacing systems, which is particularly important in an era of value-based healthcare.”
In the Micra trial, 96 percent of patients (700 of 725; six-month Kaplan-Meier estimate) practiced no major complications, which is significantly fewer - 51 percent fewer - major complications than seen in patients with conventional pacing systems (hazard ratio: 0.49; 95 percent CI, 0.33 to 0.75; P=0.001). Major complications comprised cardiac injuries (1.6 percent), complications at the groin site (0.7 percent) and pacing issues (0.3 percent). Notably, there were no (0) dislodgments, no (0) systemic infections, and very few (0.4 percent) system revisions (meaning extraction, repositioning or replacement). These low complication rates were achieved despite the inclusion of high-risk patients worldwide, counting patients with chronic obstructive pulmonary disease (COPD).
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
Finally, Shares of 3D Systems Corporation (NYSE:DDD), ended its last trade with -4.46% loss, and closed at $9.64.
3D Systems, declared that it will be taking part in form next 2015, a new trade fair for moldmaking, product design and 3D printing that will be debuting this year in Frankfurt, Germany, November 17-20.
3DS will showcase the full power of its digital thread solutions for software and 3D printing, demonstrating the seamless design-to-manufacturing workflow it enables for professionals and businesses across industries. Among the products and capabilities on display will be the Pro Jet(R) 4500, Pro Jet(R) 5500X and the Cube Pro(R) desktop 3D printer. Visitors to the show will be able to witness firsthand the accuracy and detail of the Pro X(TM) 100 Direct Metal Printer as it creates highly complex metal parts live on the show floor.
3DS’ integrated solutions enhance, complement or replace traditional manufacturing methods through 3D scanning, design, production and inspection. These solutions lead to improved part performance and raised productivity within teams and organizations.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries. The company’s 3D printers transform data input from the format generated by 3D design software, CAD software, or 3D scanning and sculpting devices to printed parts using integrated, engineered plastic, metal, nylon, rubber, wax, and composite print materials.